MOG and neuromyelitis optica: A part of those seronegative patients with clinical NMO phenotype have antibodies to myelin oligodendrocyte glycoprotein (MOG) (28, 29) and represents a relatively new disease entity called myelin oligodendrocyte glycoprotein-antibody associated disease (MOGAD) (30, 31).